Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2751 USD | +8.95% | +9.95% | -87.02% |
28/03 | Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
28/03 | ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 1M 83.4M | Sales 2025 * | - | Capitalization | 2.79M 232M |
---|---|---|---|---|---|
Net income 2024 * | -12M -1B | Net income 2025 * | - | EV / Sales 2024 * | 2.79 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.18
x | P/E ratio 2025 * |
-
| Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.85% |
Latest transcript on ENDRA Life Sciences Inc.
1 day | +10.50% | ||
1 week | +9.95% | ||
Current month | -52.57% | ||
1 month | -31.75% | ||
3 months | -73.55% | ||
6 months | -70.42% | ||
Current year | -87.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 01/15/01 | |
Irina Pestrikova
DFI | Director of Finance/CFO | 38 | 18/21/18 |
Michael Thornton
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/07/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 01/13/01 | |
Alexander Tokman
BRD | Director/Board Member | 62 | 01/08/01 |
Michael Harsh
BRD | Director/Board Member | 69 | 01/15/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 0.2751 | +8.95% | 153 802 |
26/24/26 | 0.2525 | +4.12% | 11,104 |
25/24/25 | 0.2425 | -6.69% | 35,436 |
24/24/24 | 0.2599 | +2.16% | 42,059 |
23/24/23 | 0.2544 | +1.68% | 37,025 |
Delayed Quote Nasdaq, April 29, 2024 at 10:57 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.02% | 2.79M | |
+2.45% | 42.75B | |
+47.70% | 41.61B | |
+11.87% | 41.34B | |
-8.83% | 26.59B | |
+7.04% | 25.49B | |
-22.66% | 18.12B | |
+30.65% | 12.24B | |
-1.90% | 11.76B | |
+9.19% | 11B |
- Stock Market
- Equities
- NDRA Stock